Ken Griffin Sorrento Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.74 - $1.83 $998,228 - $2.47 Million	-1,348,958 Reduced 87.08%	200,096 $178,000
Q3 2022 Nov 14, 2022	BUY	$1.51 - $2.88 $1.34 Million - $2.55 Million	884,632 Added 133.14%	1,549,054 $2.43 Million
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.33 $1.28 Million - $2.4 Million	-1,029,400 Reduced 60.77%	664,422 $1.34 Million
Q1 2022 May 16, 2022	BUY	$2.0 - $4.9 $1.38 Million - $3.39 Million	691,099 Added 68.92%	1,693,822 $3.95 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $3.6 Million - $5.6 Million	774,668 Added 339.68%	1,002,723 $4.66 Million
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $1.15 Million - $1.7 Million	154,832 Added 211.45%	228,055 $1.74 Million
Q2 2021 Aug 16, 2021	SELL	$6.35 - $10.0 $3.2 Million - $5.03 Million	-503,355 Reduced 87.3%	73,223 $709,000
Q1 2021 May 17, 2021	BUY	$7.03 - $16.51 $3.67 Million - $8.61 Million	521,598 Added 948.7%	576,578 $4.77 Million
Q4 2020 Feb 16, 2021	SELL	$5.76 - $11.95 $1,716 - $3,561	-298 Reduced 0.54%	54,980 $375,000
Q3 2020 Nov 16, 2020	SELL	$6.17 - $18.82 $2.25 Million - $6.87 Million	-364,991 Reduced 86.85%	55,278 $616,000
Q2 2020 Aug 14, 2020	BUY	$1.73 - $6.76 $210,547 - $822,719	121,704 Added 40.76%	420,269 $2.64 Million
Q3 2019 Nov 14, 2019	SELL	$2.05 - $2.69 $128,633 - $168,792	-62,748 Reduced 17.37%	298,565 $638,000
Q2 2019 Aug 14, 2019	BUY	$2.67 - $4.38 $851,324 - $1.4 Million	318,848 Added 750.85%	361,313 $965,000
Q1 2019 May 15, 2019	SELL	$1.86 - $5.94 $406,614 - $1.3 Million	-218,610 Reduced 83.73%	42,465 $0
Q4 2018 Feb 14, 2019	BUY	$2.01 - $4.24 $497,410 - $1.05 Million	247,468 Added 1818.68%	261,075 $626,000
Q3 2018 Nov 13, 2018	SELL	$4.22 - $7.5 $270,396 - $480,562	-64,075 Reduced 82.48%	13,607 $0
Q2 2018 Aug 10, 2018	BUY	$4.75 - $8.0 $255,089 - $429,624	53,703 Added 223.96%	77,682 $0
Q1 2018 May 11, 2018	BUY	$4.5 - $9.95 $51,268 - $113,360	11,393 Added 90.52%	23,979 $123,000
Q4 2017 Feb 09, 2018	SELL	$1.75 - $3.8 $35,239 - $76,520	-20,137 Reduced 61.54%	12,586 $48,000
Q3 2017 Nov 09, 2017	BUY	$1.63 - $2.0 $53,338 - $65,446	32,723	32,723 $56,000

Others Institutions Holding SRNE

# of Institutions

Shares Held

5.47M

Call Options Held

Put Options Held

View Full List

About Sorrento Therapeutics, Inc.

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

More about SRNE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account